# KEYNOTE-B15 (NCT04700124)

> Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04700124
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Bladder Cancer
- Interventions: Pembrolizumab; Enfortumab vedotin (EV); RC + PLND; Gemcitabine; Cisplatin
- Enrollment: 808
- Primary outcome: Event-Free Survival (EFS)

## Commentary we found

- X threads: 111
- YouTube: 68
- Podcasts: 46
- X videos: 5

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=keynote-b15-nct04700124

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04700124", "email": "<work email>"}; the inbox owner confirms by the emailed link.